Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $31 price target.
June 26, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Edgewise Therapeutics and maintained a $31 price target.
The reiteration of an Outperform rating and the maintenance of a $31 price target by a reputable analyst can boost investor confidence in Edgewise Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100